Drugs / Varnimcabtagene autoleucel
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03144583 | Jun 2017 → Sep 2022 | leukemia, lymphoma | Sara V. Latorre | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04778579 | May 2021 → Dec 2024 | acute lymphoblastic leukemia | Sara V. Latorre | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Varnimcabtagene autoleucel | “Varnimcabtagene autoleucel (var-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy with adaptive intra-patient dose escalation and was approved...” PMID 41651004 ↗ Feb 20261“Varnimcabtagene autoleucel (var-cel) is an academic anti-CD19 chimeric antigen receptor (CAR) product used for the treatment of non-Hodgkin lymphoma (NHL) in the CART19-BE-01 trial.” PMID 37905734 ↗ Oct 2023 |
| Known as | ARI-0001 | “Patients with B-cell malignancies receiving CD19-targeted chimeric antigen receptor (CAR) T-cell therapy may experience treatment failure due to various mechanisms. One...” PMID 40987492 ↗ Sep 2025 |
| Known as | ARI-0001 cells | “Patients with B-cell malignancies receiving CD19-targeted chimeric antigen receptor (CAR) T-cell therapy may experience treatment failure due to various mechanisms. One...” PMID 40987492 ↗ Sep 2025 |
| Known as | var-cel | “Varnimcabtagene autoleucel (var-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy with adaptive intra-patient dose escalation and was approved...” PMID 41651004 ↗ Feb 20261“Varnimcabtagene autoleucel (var-cel) is an academic anti-CD19 chimeric antigen receptor (CAR) product used for the treatment of non-Hodgkin lymphoma (NHL) in the CART19-BE-01 trial.” PMID 37905734 ↗ Oct 2023 |
| Known as | Varnimcabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314716 ↗ |
| Modality | Cell therapy | “autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy” PMID 41651004 ↗ Feb 2026 |
| Route | Intravenous | “Patients received a single course of intravenous lymphodepleting chemotherapy with fludarabine (30 mg/m2 per day for 3 days) plus cyclophosphamide (300 mg/m2 per day for 3...” PMID 41651004 ↗ Feb 2026 |
| Target | CD19 | “CD19-directed” PMID 41651004 ↗ Feb 2026 |